BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 29505494)

  • 1. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
    Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
    HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of Pre-Transplant α-fetoprotein Dynamics in Liver Transplantation for Hepatocellular Cancer.
    Grąt M; Krasnodębski M; Patkowski W; Wronka KM; Masior Ł; Stypułkowski J; Grąt K; Krawczyk M
    Ann Transplant; 2016 Feb; 21():115-24. PubMed ID: 26887339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
    Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
    Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.
    Halazun KJ; Najjar M; Abdelmessih RM; Samstein B; Griesemer AD; Guarrera JV; Kato T; Verna EC; Emond JC; Brown RS
    Ann Surg; 2017 Mar; 265(3):557-564. PubMed ID: 27611615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
    Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
    World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretransplantation α-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation.
    Dumitra TC; Dumitra S; Metrakos PP; Barkun JS; Chaudhury P; Deschênes M; Paraskevas S; Hassanain M; Tchervenkov JI
    Transplantation; 2013 Jan; 95(1):228-33. PubMed ID: 23222895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.
    Han K; Tzimas GN; Barkun JS; Metrakos P; Tchervenkov JL; Hilzenrat N; Wong P; Deschênes M
    Can J Gastroenterol; 2007 Jan; 21(1):39-45. PubMed ID: 17225881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.